Loader

Pathways

PathWhiz ID Pathway Meta Data

PW176429

Pw176429 View Pathway
metabolic

Rapacuronium Predicted Metabolism Pathway

Homo sapiens
Metabolites of Template3MB4 are predicted with biotransformer.

PW127002

Pw127002 View Pathway
metabolic

Ras

Homo sapiens

PW064776

Pw064776 View Pathway
protein

Ras Signaling Pathway

Homo sapiens
RAS signalling pathway is one of the main pathways to transduce intracellular signals in response to mitogens to controls cell growth, survival and anti-apoptotic programs. RAS proteins are GTP-binding proteins and must be bound to GTP to be active. Active RAS binds and activates effector enzymes that control cell proliferation, survival and other cell behaviours. RAS interacts directly with the catalytic subunit of PI3K to activate lipid kinases controlling the activity of downstream enzymes. Some of these kinases have anti-apoptotic activity, playing an important role in the survival signal of RAS. PI3K is also involved in the regulation of the actin cytoskeleton and transcription factor pathways. RAS also effects exchange factors causing inhibition of transcription factors from FoxO family, part of promoting cell cycle arrest and apoptosis. Normal function of these proteins require post-transcriptional modification. Pathway mutations in activation may result in human tumours.

PW109205

Pw109205 View Pathway
protein

Ras Signaling Pathway

Mus musculus
RAS signalling pathway is one of the main pathways to transduce intracellular signals in response to mitogens to controls cell growth, survival and anti-apoptotic programs. RAS proteins are GTP-binding proteins and must be bound to GTP to be active. Active RAS binds and activates effector enzymes that control cell proliferation, survival and other cell behaviours. RAS interacts directly with the catalytic subunit of PI3K to activate lipid kinases controlling the activity of downstream enzymes. Some of these kinases have anti-apoptotic activity, playing an important role in the survival signal of RAS. PI3K is also involved in the regulation of the actin cytoskeleton and transcription factor pathways. RAS also effects exchange factors causing inhibition of transcription factors from FoxO family, part of promoting cell cycle arrest and apoptosis. Normal function of these proteins require post-transcriptional modification. Pathway mutations in activation may result in human tumours.

PW109281

Pw109281 View Pathway
protein

Ras Signaling Pathway

Rattus norvegicus
RAS signalling pathway is one of the main pathways to transduce intracellular signals in response to mitogens to controls cell growth, survival and anti-apoptotic programs. RAS proteins are GTP-binding proteins and must be bound to GTP to be active. Active RAS binds and activates effector enzymes that control cell proliferation, survival and other cell behaviours. RAS interacts directly with the catalytic subunit of PI3K to activate lipid kinases controlling the activity of downstream enzymes. Some of these kinases have anti-apoptotic activity, playing an important role in the survival signal of RAS. PI3K is also involved in the regulation of the actin cytoskeleton and transcription factor pathways. RAS also effects exchange factors causing inhibition of transcription factors from FoxO family, part of promoting cell cycle arrest and apoptosis. Normal function of these proteins require post-transcriptional modification. Pathway mutations in activation may result in human tumours.

PW109252

Pw109252 View Pathway
protein

Ras Signaling Pathway

Bos taurus
RAS signalling pathway is one of the main pathways to transduce intracellular signals in response to mitogens to controls cell growth, survival and anti-apoptotic programs. RAS proteins are GTP-binding proteins and must be bound to GTP to be active. Active RAS binds and activates effector enzymes that control cell proliferation, survival and other cell behaviours. RAS interacts directly with the catalytic subunit of PI3K to activate lipid kinases controlling the activity of downstream enzymes. Some of these kinases have anti-apoptotic activity, playing an important role in the survival signal of RAS. PI3K is also involved in the regulation of the actin cytoskeleton and transcription factor pathways. RAS also effects exchange factors causing inhibition of transcription factors from FoxO family, part of promoting cell cycle arrest and apoptosis. Normal function of these proteins require post-transcriptional modification. Pathway mutations in activation may result in human tumours.

PW128313

Pw128313 View Pathway
drug action

Rasagiline Action Pathway

Homo sapiens
Rasagiline is a propargylamine and an irreversible monoamine oxidase inhibitor (MAOIs). It is indicated in the treatment of idiopathic Parkinson's disease as initial therapy or as adjunct therapy with levodopa. The monoamine oxidase is an enzyme that catalyzes the oxidative deamination of many amines like serotonin, norepinephrine, epinephrine, and dopamine. There are 2 isoforms of this protein: A and B. The first one is found in cells located in the periphery and breakdown serotonin, norepinephrine, epinephrine, dopamine, and tyramine. The second one, the B isoform, breakdowns phenylethylamine, norepinephrine, epinephrine, dopamine, and tyramine. This isoform is found in the extracellular tissues and mostly in the brain. The mechanism of action of the MAOIs is still not determined, it is thought that they act by increasing free serotonin and norepinephrine concentrations and/or by altering the concentrations of other amines in the CNS. MAO-A inhibition is thought to be more relevant to antidepressant activity than the inhibition caused by MAO B. Selective MAO B inhibitors have no antidepressant effects. The selectivity of rasagiline for inhibiting only MAO-B results in more dopamine in the cytosol and synapse of the neurons in the striatum. The increased dopamine level thus increases the dopaminergic activity. This helps to reduce the symptoms of Parkinson's disease that are caused by low levels of dopamine in the striatum. An overdose of this drug will result in drowsiness, faintness, hyperactivity, hallucinations, respiratory depression, convulsions, and coma. This drug is administered as an oral tablet.

PW145399

Pw145399 View Pathway
drug action

Rasagiline Drug Metabolism Action Pathway

Homo sapiens

PW146421

Pw146421 View Pathway
drug action

Rebamipide Drug Metabolism Action Pathway

Homo sapiens

PW176516

Pw176516 View Pathway
metabolic

Rebamipide Predicted Metabolism Pathway

Homo sapiens
Metabolites of Rebamipide are predicted with biotransformer.